Krystal Biotech, Inc. · NASDAQ:KRYS
Krystal Biotech — Corporate Update (August 2024)
32 slides from Krystal Biotech's corporate update, August 2024
Slide 1: KB301 PEARL-1 Interim Results for Dynamic Wrinkles of the Décolleté and Lateral Canthal Lines
Revolutionizing Aesthetic Medicine KB301 PEARL-1 Interim Results for Dynamic Wrinkles of the Décolleté and Lateral Canthal Lines August 2024 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation, which includes the accompanying oral presentation, contains, and the answers to questions may contain, forward-looking statements that involve substantial risks and uncertainties. Any statements in this presentation about future expectations, plans and p
Slide 3: Jeune Aesthetics: Wholly Owned Subsidiary of Krystal Biotech, Inc.
Jeune Aesthetics: Wholly Owned Subsidiary of Krystal Biotech, Inc. Fully integrated biotech developing portfolio of genetic medicines R&D Regulatory Subsidiary Dedicated to Aesthetics and Cash Pay Markets* ✓ Clinical Development ✓ Commercial Manufacturing Legal Finance / HR *Jeune holds exclusive li
Slide 4: Lead Program KB301 Designed to Increase Type III Collagen Levels in Aging Skin
Lead Program KB301 Designed to Increase Type III Collagen Levels in Aging Skin KB301 Phase 1 Program PEARL-1 Cohort 1 – Safety and PK* KB301 Payload Cohort 2 – Initial Efficacy** • Type III collagen (COL3) is the second most abundant protein in the skin but levels decline significantly with age • CO
Slide 5: Aesthetic Improvement Reported at All KB301 Treatment Sites in Cohort 2
Aesthetic Improvement Reported at All KB301 Treatment Sites in Cohort 2 Cohort 2: Exploratory, 2:1 randomized, placebo-controlled study evaluating safety and efficacy of KB301, administered up to four times weekly, at either low and/or high dose, to the area above the knee, the lower cheek and upper
Slide 6: Durability of at Least Nine Months Observed in Extension Follow Up
Durability of at Least Nine Months Observed in Extension Follow Up Change in Subject Satisfaction Score Lower Cheek High Dose Group 2 1.8 1.6 Mean Change in SSS Scores remained elevated from 1.4 7 to 9 months baseline approximately 7-9 months from Baseline 5-6 months 1.2 after last dose after the la
Slide 7: Indications for Cohorts 3/4 Selected Based on KB301 Profile and Market Demand
Indications for Cohorts 3/4 Selected Based on KB301 Profile and Market Demand Cohort 3 Lateral Canthal Lines at Rest Cohort 4 Dynamic Wrinkles of the Décolleté 7 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved.
Slide 8: Cohorts 3 and 4 Interim Data Review
Cohorts 3 and 4 Interim Data Review 8
Slide 9: PEARL-1 Cohort 3 Evaluating KB301 in Lateral Canthal Lines at Rest
PEARL-1 Cohort 3 Evaluating KB301 in Lateral Canthal Lines at Rest Study Objective and Design • Multicenter, open-label study evaluating KB301 for the improvement of lateral Abbreviated Treatment and Assessment canthal lines at rest in adults Schedule for Interim Readout • Key study objectives were
Slide 10: Interim Safety Findings in Lateral Canthal Region
Interim Safety Findings in Lateral Canthal Region Both low and high dose KB301 generally well tolerated with no adverse change in safety profile upon repeat dosing Localized, Related or Possibly Related Adverse Events* Grade 1 Grade 2 Grade 3 Grade 4 Dryness 2 0 0 0 Erosion 0 2 0 0 Itching 6 0 0 0 P
Slide 11: Clear and Clinically Meaningful Improvements in Lateral Canthal Lines
Clear and Clinically Meaningful Improvements in Lateral Canthal Lines GAIS Results for Wrinkles / Lines Subject Satisfaction Responder Rate* Subject Assessed Investigator Assessed Lateral Canthal Lines; Two Month Follow Up 100% 100% 80% 80% +2 Point = (Much) Improved +1 Point = Somewhat Improved 60%
Slide 12: Improvements Also Observed Across Multiple Other Skin Attributes
Improvements Also Observed Across Multiple Other Skin Attributes GAIS Responder Rates* by Attribute Subject Assessed Investigator Assessed 100% 100% Crepiness 80% 80% Elasticity 60% 60% Hydration Radiance 40% 40% Texture 20% 20% 0% 0% One Month Two Month One Month Two Month Follow Up Period Follow U
Slide 13: Lateral Canthal Lines Before and After Images
Lateral Canthal Lines Before and After Images Baseline Two Month Follow Up 13 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved.
Slide 14: Lateral Canthal Lines Before and After Images
Lateral Canthal Lines Before and After Images Baseline Two Month Follow Up 14 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved.
Slide 15: PEARL-1 Cohort 4 Evaluating KB301 in Dynamic Wrinkles of the Décolleté
PEARL-1 Cohort 4 Evaluating KB301 in Dynamic Wrinkles of the Décolleté Abbreviated Treatment and Assessment Study Objective and Design Schedule for Interim Readout • Multicenter, open-label study evaluating KB301 for the improvement of dynamic wrinkles of the décolleté in adults Treatment Visits • K
Slide 16: Interim Safety Findings in the Décolleté Region
Interim Safety Findings in the Décolleté Region KB301 generally well tolerated with no adverse change in safety profile upon repeat dosing Localized, Related or Possibly Related Adverse Events* Grade 1 Grade 2 Grade 3 Grade 4 Bumps 14 1 0 0 Burning 1 0 0 0 Discomfort 0 1 0 0 Edema 1 0 0 0 Hypersensi
Slide 17: Profound Improvements Increasing With Time in the Décolleté
Profound Improvements Increasing With Time in the Décolleté GAIS Results for Wrinkles / Lines Subject Satisfaction Responder Rate* Subject Assessed Investigator Assessed Dynamic Wrinkles; Two Month Follow Up 100% 100% 80% 80% +2 Point = (Much) Improved +1 Point = Somewhat Improved 60% 60% 0 Point =
Slide 18: Again Seeing Improvements Across Multiple Other Skin Attributes
Again Seeing Improvements Across Multiple Other Skin Attributes GAIS Responder Rates* by Attribute Subject Assessed Investigator Assessed 100% 100% Crepiness 80% 80% Elasticity 60% 60% Hydration Radiance 40% 40% Texture 20% 20% 0% 0% One Month Two Month One Month Two Month Follow Up Period Follow Up
Slide 19: Décolleté Before and After Images
Décolleté Before and After Images Baseline Two Month Follow Up 19 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved.
Slide 20: Décolleté Before and After Images
Décolleté Before and After Images Baseline Two Month Follow Up 20 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved.
Slide 21: Décolleté Before and After Images
Décolleté Before and After Images Baseline Two Month Follow Up 21 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved.
Slide 22: Next Steps and Market Opportunity
Next Steps and Market Opportunity 22
Slide 23: Next Steps for KB301
Next Steps for KB301 ✓ ❑ Select indication for Phase 2 development – completed, décolleté selected ❑ Develop KB301-specific scale and assessment tool for patient report outcomes ❑ Initiate Phase 2 development – target study start 2025 23 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved.
Slide 24: No Primary Aesthetic Tool Addresses Aged Skin
No Primary Aesthetic Tool Addresses Aged Skin Fillers: Fat and Bone Loss Neuromodulators: Dynamic Wrinkles NO PRIMARY TOOL Aged Skin 24 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved.
Slide 25: Ideal Primary Tool for Skin Rejuvenation
Ideal Primary Tool for Skin Rejuvenation Jeune Jeune Jeune Jeune Technology Technology Technology Technology Address Root Injected with Shipped and No Capital Cause of Skin Standard Stored like other Equipment Aging Syringes and Injectables Investment Needles 25 © Copyright 2024 Jeune Aesthetics, In
Slide 26: Significant Existing Consumer Demand
Significant Existing Consumer Demand 4.5M Aesthetic Injection Consumers Globally1 No FDA Approved Aesthetic Injectables for the Décolleté The Décolleté: New Emphasis is Being Given to Keeping the Area as Fresh as your Face2 1 International Society of Plastic Surgery, Global Survey, 2022. Consumer nu
Slide 27: Significant Market Expansion Trends
Significant Market Expansion Trends Prejuvenation2 Increasing Demand due Growing Skin Rejuvenation Market1 to GLP-1 Accelerated Growth of Minimally Skin Aging3 Invasive Procedures in WW Annual Expenditure Millennials Collagen and Elastin $24.6B 2023 Damage in Skin due to Gen Z is 22% of Global Signi
Slide 28: Projected Aesthetic Treatment Ladder
Projected Aesthetic Treatment Ladder Addition of Neurotoxin Aesthetic Practice Visit and Filler Skin Rejuvenation OTC Beauty Lotions with Jeune Technology 28 © Copyright 2024 Jeune Aesthetics, Inc. All rights reserved.
Slide 29: Market Size
Market Size Fillers: Fat and Bone Loss Neuromodulators: $5B $4B Dynamic Wrinkles $5B Aged Skin POTENTIAL MARKET Global filler revenue : https://www.fortunebusinessinsights.com/industry-reports/dermal-fillers-market-100939 Global neuromodulators revenue: AbbVie earnings and Aesthetics Market Resilien
Slide 30: Deep Pipeline Targeting Priority Extracellular Matrix Proteins Including Elastin
Deep Pipeline Targeting Priority Extracellular Matrix Proteins Including Elastin KB303 for the Delivery of Elastin • Late preclinical stage program with data package to support Jeune Aesthetics Pipeline progression into clinic for treatment of skin elasticity loss • Transduction and elastin secretio
Slide 31: Long Term Strategic Vision for Jeune
Long Term Strategic Vision for Jeune ▪ Krystal well-positioned to rapidly advance KB301 through value-creating Phase 2 milestones ▪ As KB301 progresses in the clinic, need for dedicated resource and commercial aesthetics Vision: Creating a new segment of expertise will grow fundamentally rejuvenativ
Slide 32: Closing and Q&A
=\ Closthg and \) QSA\ — & \ ~ ~ aa JEUNE